We are live on ! Find out more
MLYS icon

Mineralys Therapeutics
MLYS

67 hedge funds and large institutions have $385M invested in Mineralys Therapeutics in 2023 Q1 according to their latest regulatory filings, with 67 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

60.24% more ownership

Funds ownership: 0% → 60.24% (+60%)

Holders
67
Holders Change
+67
Holders Change %
–
% of All Funds
1.07%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.05%
New
67
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SB
Samsara BioCapital
California
+$76.1M
2
RCM
RA Capital Management
Massachusetts
+$53.5M
3
ASP
Adams Street Partners
Illinois
+$40.7M
4
SOCM
SR One Capital Management
Pennsylvania
+$30.2M
5
APM
Avidity Partners Management
Texas
+$21.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
WP
26
Woodline Partners
California
$2.74M +$2.95M +175,000 New
State Street
27
State Street
Massachusetts
$2.11M +$2.27M +134,800 New
Ensign Peak Advisors
28
Ensign Peak Advisors
Utah
$1.96M +$2.1M +125,000 New
OM
29
Opaleye Management
Massachusetts
$1.8M +$1.94M +115,000 New
MIM
30
Monashee Investment Management
Massachusetts
$1.72M +$1.85M +110,000 New
Northern Trust
31
Northern Trust
Illinois
$1.57M +$1.69M +100,477 New
Charles Schwab
32
Charles Schwab
California
$1.39M +$1.5M +88,960 New
SSA
33
Schonfeld Strategic Advisors
New York
$1.39M +$1.5M +88,848 New
PCM
34
Pentwater Capital Management
Florida
$1.1M +$1.18M +70,000 New
AAA
35
Affinity Asset Advisors
New York
$979K +$1.05M +62,500 New
ACH
36
ArrowMark Colorado Holdings
Colorado
$979K +$1.05M +62,500 New
Prudential Financial
37
Prudential Financial
New Jersey
$792K +$851K +50,570 New
Alyeska Investment Group
38
Alyeska Investment Group
Illinois
$587K +$631K +37,500 New
PMEF
39
Point72 Middle East FZE
United Arab Emirates
$577K +$620K +36,822 New
Bank of New York Mellon
40
Bank of New York Mellon
New York
$521K +$560K +33,286 New
Morgan Stanley
41
Morgan Stanley
New York
$471K +$506K +30,051 New
Goldman Sachs
42
Goldman Sachs
New York
$435K +$467K +27,765 New
Walleye Capital
43
Walleye Capital
New York
$407K +$438K +25,996 New
Wellington Management Group
44
Wellington Management Group
Massachusetts
$379K +$408K +24,224 New
N
45
Nuveen
North Carolina
$253K +$272K +16,134 New
Bank of America
46
Bank of America
North Carolina
$219K +$236K +13,990 New
Barclays
47
Barclays
United Kingdom
$196K +$211K +12,536 New
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$172K +$184K +10,960 New
CSS
49
Cubist Systematic Strategies
Connecticut
$160K +$172K +10,227 New
GCM
50
Ghisallo Capital Management
Massachusetts
$157K +$168K +10,000 New
1
2
3

MLYS Hedge Fund Activity: Q1 2023 in Review

67 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Mineralys Therapeutics (MLYS) for Q1 2023, worth a combined $385M.

Buyers outnumbered sellers: 67 funds opened new MLYS positions and 0 closed out — a net gain of 67 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Samsara BioCapital, opening a new position worth an estimated $76.1M.

  • 67 institutional investors held Mineralys Therapeutics (MLYS) as of Q1 2023, up from 0 in Q4 2022.
  • Funds reported $385M of Mineralys Therapeutics stock for Q1 2023.
  • 67 funds opened new Mineralys Therapeutics positions in Q1 2023 and 0 closed out, a net change of +67 holders.
  • The largest Mineralys Therapeutics buyer in Q1 2023 was Samsara BioCapital, an estimated $76.1M added.

Based on aggregated 13F filings for Q1 2023.